AXTI

AXT is a small compound-semiconductor substrate maker (indium phosphide, gallium arsenide, germanium) whose stock has been swept up in AI/optical-datacenter speculation, leaving a stark gap between price and fundamentals. The market cap is $4.70B against just $88.3M of revenue — an extraordinary 53.2x sales — yet the underlying business is contracting and unprofitable: revenue fell 11.1% to $88.3M, gross profit dropped 52.8% to $11.2M (a thin 12.7% gross margin), and the company posted a net loss of $21.3M (EPS -$0.49), its third straight annual loss after earning $14.6-15.8M in FY2021-2022.

The operating trajectory is poor. Operating income was -$22.0M (a -24.9% margin), operating cash flow was negative at -$12.8M, and R&D was actually cut 37.8% to $9.05M — hardly the spending profile of a company about to capitalize on a generational demand wave. The company funds itself through a sprawl of dozens of short-term Chinese bank loans (~$58.6M total, from Bank of China, ICBC, Bank of Beijing and others), and raised equity (shares up 21.9%), lifting cash to $120M but diluting holders. Its manufacturing and financing are concentrated in China, adding currency, geopolitical and export-control risk.